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INTRODUCTION
Necrotising fasciitis (NF) is a type of soft tissue infection that 
spreads rapidly and progressively along the deep fascia. It is a 
life‑threatening disease with a course that is often overwhelming 
in nature. Despite improved medical care, the mortality rate 
associated with NF remains between 12% and 34%.(1‑4) Mortality 
is especially high among cirrhotic patients with NF, in whom rates 
have been reported to be nearly ninefold that among non‑cirrhotic 
patients with NF.(1‑4)
Liver cirrhosis can weaken the intestinal‑portal route barrier, 
which facilitates the entry of bacteria into the systemic circulation 
and renders patients prone to various infectious diseases such 
as spontaneous bacterial peritonitis, respiratory infections or 
urinary tract infections.(5,6) Several reports have shown that liver 
cirrhosis is a common underlying disease in patients with NF.(1‑4,7,8) 
However, it remains unknown whether liver cirrhosis can increase 
the occurrence of NF.
The purpose of this study was twofold, namely to determine 
whether liver cirrhosis is an independent risk factor for the 
occurrence of NF, and to identify the relationship between 
severity of liver cirrhosis and occurrence of NF.
METHODS
This study was approved by the National Health Research 
Institutes (NHRI) in Taiwan. The National Health Insurance 
Research Database (NHIRD), established and maintained by 
the Bureau of National Health Insurance (BNHI), Taiwan, and 
the NHRI, was used for the purpose of the present study. This 
database includes all data regarding hospitalised patients in 
Taiwan. The National Health Insurance (NHI) programme was 
established in 1995 and encompasses all citizens residing in 
Taiwan. The BNHI covers over 98% of Taiwan’s population. 
Although researchers are welcome to use the NHIRD for their 
studies, the privacy of patients and healthcare providers is 
protected, as researchers using the database are required to submit 
their study protocols for evaluation by the NHRI.
In this retrospective study, hospitalised patients diagnosed 
with liver cirrhosis (in accordance with the International 
Classification of Diseases, 9th Revision, Clinical Modification 
[ICD‑9‑CM] code 571.5 or 571.2 in the NHIRD) between 
1 January 2004 and 31 December 2004 were included for 
analysis. Patients aged less than 30 years were excluded from 
the study, as the aetiologies of liver cirrhosis in such patients are 
often different from those of other cirrhotic patients. Patients with 
missing or incomplete medical data were also excluded.
As per Taiwan’s NHI directives, cirrhotic patients with 
refractory ascites, episodes of oesophageal/gastric variceal 
bleeding or hepatic encephalopathy can obtain certification 
to reduce hospitalisation payments. Cirrhotic patients who 
availed such certification were identified from the database and 
categorised as those having complicated liver cirrhosis.
A total of 40,802 cirrhotic patients without baseline NF were 
enrolled in our study. Cirrhotic patients were stratified according 
to gender and age (age groups: 30–44 years; 45–59 years; 
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60–74 years; > 75 years). Age‑ and gender‑matched non‑cirrhotic 
patients without baseline NF were also randomly selected from 
the database as the control group (n = 40,865). All patients 
(n = 81,667) were individually followed up for a three‑year 
period, beginning with their first hospitalisation in 2004 until the 
diagnosis of NF (in accordance with ICD‑9‑CM codes 728.86), 
death, loss to follow‑up or the end of study.
Time to development of NF was defined as the duration from 
the date selected for follow‑up to the time of hospitalisation 
for NF. The medical comorbidities selected for the study were 
alcoholism (ICD‑9‑CM codes 291, 303, 305.00‑305.03 and 
571.0‑571.3), diabetes mellitus (DM; ICD‑9‑CM code 250), 
chronic renal failure (CRF; ICD‑9‑CM code 585), solid organ 
transplantation (SOT; ICD‑9‑CM codes V42.0, V42.1 and V42.7), 
human immunodeficiency virus (HIV) infection (ICD‑9‑CM 
code 042), malignancy (ICD‑9‑CM code 140‑208) and connective 
tissue disease (CTD; ICD‑9‑CM codes 710). Comorbidities were 
identified from the patients’ hospitalisation records available prior 
to the end of follow‑up. The term ‘censored’ was used to indicate 
patient death, patients lost to follow‑up or the end of study.
Data was analysed using the Statistical Package for the Social 
Sciences for Windows version 13.0 (SPSS Inc, Chicago, IL, USA). 
Cox regression was used to model all factors associated with 
time to hospitalisation for NF. Age was entered into the Cox 
models as a continuous covariable using the following coding: 
1 = 30–44 years; 2 = 45–59 years; 3 = 60–74 years; 4 = > 75 years. 
Potential confounding factors included in the analysis were DM, 
CRF, alcoholism, malignancy, age groups, SOT, gender, CTD 
and HIV infection. Hazard ratios (HRs) and 95% confidence 
intervals (CIs) were presented, with the significance level fixed 
at p‑value ≤ 0.05. The R software for Windows (available at: 
http://cran.r‑project.org/bin/windows/base/) was used to plot the 
estimated cumulative incidence curves and perform competing 
risk analysis.(9)
RESULTS
Table I shows the demographic characteristics and comorbidities 
of cirrhotic and non‑cirrhotic patients enrolled in the study. 
A total of 81,667 patients were enrolled, and the mean age of 
the cohort was 59.3 ± 14.3 years. Among the 40,802 cirrhotic 
patients, 8,739 (21.4%) patients had complicated liver cirrhosis 
and 32,063 (78.6%) patients had non‑complicated liver 
cirrhosis. During the three‑year follow‑up period, NF occurred 
in 299 (0.7%) cirrhotic patients and 160 (0.4%) non‑cirrhotic 
patients. The distribution of many of the comorbidities was found 
to be significantly different between cirrhotic and non‑cirrhotic 
patients.
Table II provides the results of Cox regression analysis of 
the various confounding factors for the occurrence of NF in all 
patients during the study. Significant positive correlation was 
found between the occurrence of NF and variables such as liver 
cirrhosis (HR 1.982; p < 0.001), DM (HR 2.978; p < 0.001), CRF 
(HR 1.615; p = 0.030) and alcoholism (HR 1.364; p = 0.018). 
Similarly, significant negative correlation was found between 
the occurrence of NF and variables such as old age (HR 0.759; 
p < 0.001) and malignancy (HR 0.462; p < 0.001).
Table III shows the demographic characteristics and 
comorbidities of patients with complicated and non‑complicated 
cirrhosis. The distribution of many comorbidities and age 
groups were significantly different between cirrhotic patients 
with and without complicated liver cirrhosis. During the 
three‑year follow‑up period, NF occurred in 95 (1.1%) patients 
with complicated cirrhosis and 204 (0.6%) patients with 
non‑complicated cirrhosis. As only 15 cirrhotic patients had HIV 
infection, HIV infection was not entered as a variable into the 
Cox regression model.
Table I. Characteristics of cirrhotic and non‑cirrhotic patients.
Variable No. of patients (%) p‑value
Cirrhotic 
(n = 40,802)
Non‑cirrhotic 
(n = 40,865)
Gender
Male
Female
29,010 (71.1)
11,792 (28.9)
29,067 (71.1)
11,798 (28.9)
0.925
Age group (yrs)
30–44
45–59
60–74
> 75
7,073 (17.3)
13,069 (32.0)
14,150 (34.7)
6,510 (16.0)
7,097 (17.4)
13,098 (32.1)
14,162 (34.7)
6,508 (15.9)
0.999
Comorbidities
CTD
DM
CRF
Alcoholism
SOT
HIV infection
Malignancy
60 (0.1)
8,010 (19.6)
1,249 (3.1)
7,950 (19.5)
129 (0.3)
15 (0.0)
13,432 (32.9)
77 (0.2)
7,168 (17.5)
1,151 (2.8)
684 (1.7)
77 (0.2)
20 (0.0)
5,319 (13.0)
0.149
< 0.001*
0.039*
< 0.001*
< 0.001*
0.400
< 0.001*
Complicated liver 
cirrhosis
Yes
No
Occurrence of NF
 
8,739 (21.4)
32,063 (78.6)
299 (0.7)
 
0
0
160 (0.4)
 
‑
‑
< 0.001*
*p ≤ 0.05 was considered statistically significant. CTD: connective tissue disease; 
CRF: chronic renal failure; DM: diabetes mellitus; HIV: human immunodeficiency 
virus; NF: necrotising fasciitis; SOT: solid organ transplantation
Table II. Cox regression analysis of confounding factors for the 
occurrence of necrotising fasciitis in cirrhotic and non‑cirrhotic 
patients.
Variable Hazard ratio (95% CI) p‑value
Liver cirrhosis 1.982 (1.609–2.441) < 0.001†
Diabetes mellitus 2.978 (2.460–3.605) < 0.001†
Chronic renal failure 1.615 (1.049–2.488) 0.030†
Alcoholism 1.364 (1.054–1.765) 0.018†
Malignancy 0.462 (0.340–0.627) < 0.001†
Old age* 0.759 (0.679–0.848) < 0.001†
SOT 0.740 (0.104–5.271) 0.763
Male gender 1.039 (0.829–1.303) 0.739
Connective tissue disease 3.288 (0.815–13.266) 0.094
HIV infection 6.246 (0.875–44.577) 0.068
*Old age was entered into the Cox regression models as a continuous covariable 
using the following coding: 1 = 30–44 years; 2 = 45–59 years; 3 = 60–74 years; 
4 = > 75 years. †p ≤ 0.05 was considered statistically significant. CI: confidence 
interval; HIV: human immunodeficiency virus; SOT: solid organ transplantation
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Table IV shows the results of Cox regression analysis of the 
various confounding factors for the occurrence of NF in cirrhotic 
patients during the study period. Significant positive correlation 
was found between the occurrence of NF and variables such as 
complicated liver cirrhosis (HR 1.320; p = 0.028), DM (HR 1.957; 
p < 0.001) and CTD (HR 4.996; p = 0.025). However, significant 
negative correlation was found between the occurrence of NF and 
variables such as old age (HR 0.642; p < 0.001) and malignancy 
(HR 0.416; p < 0.001).
Estimated cumulative incidence curves were constructed 
for time to hospitalisation for NF in cirrhotic (n = 40,802) and 
non‑cirrhotic patients (n = 40,865) after the three‑year follow‑up 
(Fig. 1). Results of Gray’s test for equality of cumulative incidence 
functions across groups showed that cumulative incidence curves 
for cirrhotic and non‑cirrhotic patients were statistically different 
for the occurrence of NF.
DISCUSSION
The overall incidence of NF has been estimated to range between 
0.24–0.4 per 100,000 adults.(10‑12) In a large survey of Canadian 
children, Eneli and Davies found that the incidence of NF caused 
by Group A streptococci was 0.21 per 100,000 children, while 
that of NF caused by non‑Group A streptococci was 0.08 per 
100,000 children.(13) In the present study, we found that, in addition 
to the incidence of NF in cirrhotic patients (0.7%), the occurrence 
rate of NF in non‑cirrhotic patients (0.4%) was also much higher 
than reported in the literature. This may partly be due to the fact that 
those enrolled in our study were all hospitalised patients who often 
already have comorbidities that contribute to their hospitalisation.
In Taiwan, liver cirrhosis in most adult patients is related 
to either the hepatitis B or hepatitis C virus.(14,15) In our study, 
alcoholism accounted for liver cirrhosis in only 19.5% of cirrhotic 
patients, with liver cirrhosis in the remaining 80.5% of cirrhotic 
patients being related to viral hepatitis. Our findings suggest that 
alcoholism was not a key factor affecting the occurrence of NF 
in cirrhotic populations. We also found that liver cirrhosis itself 
could increase the risk of occurrence of NF. Other risk factors 
that were identified for the occurrence of NF in the present study 
included DM, CRF and alcoholism. Our results were compatible 
with the findings of earlier studies.(4,8,16‑20) However, to our 
knowledge, no previous cohort study in the literature has proven 
that liver cirrhosis is a risk factor for the occurrence of NF.
Earlier studies have suggested that NF was slightly more 
common in patients aged above 50 years(10,20‑23) and that 
malignancy was a contributing factor for NF due to impaired 
leucocyte function in such patients.(18,24,25) Contrary to these 
studies, we found that malignancy and age groups were negatively 
correlated with the occurrence of NF during the three‑year 
follow‑up period. These findings may have been influenced by the 
fact that patient death was indicated as ‘censored’ in our study. 
Apart from patient deaths, hospitalised patients with malignancy 
or old age during the three‑year follow‑up period were also 
considered as censors. Such categorisation – when few episodes 
of NF are observed with a large number of censors – may have 
given rise to some bias and caused an underestimation of the 
effect of age and malignancy on the occurrence of NF.
An antecedent traumatic wound, which may include trauma, 
intravenous or hypodermic injection, or surgery, has been 
suggested as a possible portal of entry for NF.(26,27) However, 
studies have also found that most cirrhotic patients with NF 
do not have obvious lesions on the body surface that allow 
bacterial invasion.(2,7,16) Monomicrobial NF is reported to be 
more common in cirrhotic patients,(2,16) unlike patients with DM, 
in whom NF is reported to be mainly polymicrobial.(2,16) Studies 
have also suggested that Gram‑negative bacilli such as Vibrio 
spp., Klebsiella spp. and Aeromonas spp. are common causes 
of monomicrobial NF in cirrhotic patients, while Streptococcus 
pyogenes is commonly seen in patients with DM.(2,7,16) These 
Table III. Characteristics of all patients with complicated and 
non‑complicated liver cirrhosis (n = 40,802).
Variable No. of cirrhotic patients (%) p‑value
Non‑ 
complicated 
(n = 32,063)
Complicated 
(n = 8,739)
Gender
Male
Female
22,758 (71.0)
9,305 (29.0)
6,252 (71.5)
2,487 (28.5)
0.304
Age group (yrs)
30–44
45–59
60–74
> 75
5,087 (15.9)
9,611 (30.0)
11,611 (36.2)
5,754 (17.9)
1,986 (22.7)
3,458 (39.6)
2,539 (29.1)
756 (8.7)
< 0.001*
Comorbidities
CTD
DM
CRF
Alcoholism
SOT
HIV infection
Malignancy
Occurrence of NF
49 (0.2) 
6,163 (19.2)
1,054 (3.3) 
5,662 (17.7)
74 (0.2)
13 (0)
12,157 (37.9)
204 (0.6)
11 (0.1) 
1,847 (21.1)
195 (2.2) 
2,288 (26.2)
55 (0.6)
2 (0)
1,275 (14.6)
95 (1.1)
0.671 
< 0.001*
< 0.001* 
< 0.001*
< 0.001*
0.752
< 0.001*
< 0.001*
*p ≤ 0.05 was considered statistically significant. CTD: connective tissue disease; 
CRF: chronic renal failure; DM: diabetes mellitus; HIV: human immunodeficiency 
virus; NF: necrotising fasciitis; SOT: solid organ transplantation
Table IV. Cox regression analysis of confounding factors for the 
occurrence of necrotising fasciitis in patients with complicated and 
non‑complicated liver cirrhosis.
Variable Hazard ratio (95% CI) p‑value
Complicated liver cirrhosis* 1.320 (1.031–1.690) 0.028‡
Diabetes mellitus 1.957 (1.527–2.508) < 0.001‡
Connective tissue disease 4.996 (1.225–20.371) 0.025‡
Malignancy 0.416 (0.290–0.598) < 0.001‡
Old age† 0.642 (0.557–0.741) < 0.001‡
Alcoholism 1.137 (0.867–1.492) 0.354
Solid organ transplantation 0.893 (0.125–6.374) 0.910
Male gender 0.967 (0.725–1.290) 0.820
Chronic renal failure 1.133 (0.581–2.209) 0.713
*In comparison with non‑complicated liver cirrhosis. †Old age was entered into 
the Cox regression models as a continuous covariable using the following coding: 
1 = 30–44 years; 2 = 45–59 years; 3 = 60–74 years; 4 = > 75 years. ‡p ≤ 0.05 was 
considered statistically significant. CI: confidence interval
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findings suggest that the clinical setting of NF in cirrhotic patients 
is different from that in other debilitated individuals. A possible 
mechanism of NF in cirrhotic patients includes the seeding of 
bacteria in the oedematous soft tissue via the bloodstream through 
the intestinal portal route.(2,7) Such aetiology may explain why 
the simultaneous involvement of two extremities is seen in 28% 
of cirrhotic patients with NF, with 58% of these patients having 
concurrent Gram‑negative bacteraemia.(2)
In cirrhotic patients, intestinal bacterial overgrowth and 
increased intestinal permeability contribute to bacterial 
translocation from the intestines more easily than in normal 
hosts.(28‑32) The concomitant presence of impaired phagocytosis, 
poor opsonisation capacity, impaired reticuloendothelial system 
and low complement levels in cirrhotic patients(33‑37) makes them 
all the more prone to bacteraemia.(38‑40) Kuo et al reported that 
the frequencies of bacteraemia were positively correlated to the 
severity of liver cirrhosis.(41) This might explain our finding that 
patients with liver cirrhosis had a higher occurrence of NF, and 
this was especially so among patients with complicated liver 
cirrhosis.
In our study, CTD was not a risk factor for the occurrence of 
NF in all patients, although it was a risk factor for the occurrence 
of NF in cirrhotic patients. This suggests that CTD and liver 
cirrhosis have a synergistic effect on the occurrence of NF. 
However, the immunosuppressive status caused by CTD or the 
immunosuppressive therapies usually prescribed for CTD is not 
a sufficient cause for bacterial blood stream infections leading 
to NF. This notwithstanding, the immunosuppressive effects of 
CTD may further weaken the immune status of cirrhotic patients, 
thus contributing to higher bacterial bloodstream infection and 
increased occurrence of NF in this cohort. Further extensive 
studies will be required to establish this association.
There were some limitations to our study. First, all selected 
patients were hospitalised patients and non‑cirrhotic patients 
were selected as the control group in accordance with the 
diagnostic criteria outlined in the ICD‑9‑CM. This may have led 
to some bias, as patients who had liver cirrhosis but were not 
diagnosed during hospitalisation would have been categorised 
as non‑cirrhotic patients in our study. Next, laboratory data 
regarding bilirubin, albumin and prothrombin time could not 
be identified based on the ICD‑9‑CM coding from the database. 
Similarly, we could not evaluate the severity of liver cirrhosis 
based on the Child‑Pugh score. Then, the database used in our 
study did not include complete information on individuals, such 
as the amount of alcohol consumed, or dosage and duration of 
steroid use. This may have somewhat influenced the results of 
our study. Furthermore, we could not discount the possibility 
of miscoding, or assess the validity of NF diagnosis in our 
database. Finally, the exact aetiology of liver cirrhosis was not 
identified in our national population‑based study. However, 
despite its limitations, our study is the most complete nationwide 
population‑based study to prove that liver cirrhosis is a risk factor 
for the occurrence of NF.
To summarise, we found that cirrhotic patients had a higher 
risk for the occurrence of NF than non‑cirrhotic patients, and the 
risk for NF was especially high among patients with complicated 
liver cirrhosis. DM, CRF and alcoholism were risk factors for the 
occurrence of NF in both cirrhotic and non‑cirrhotic patients, 
while CTD was a risk factor for NF in only cirrhotic patients. Old 
age and malignancy were negatively associated with NF. Future 
studies should aim to investigate and substantiate the associations 
noted in this study.
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